Literature DB >> 3075131

The current status of the dopamine hypothesis of schizophrenia.

A Carlsson1.   

Abstract

The dopamine hypothesis of schizophrenia is still almost entirely based on pharmacologic evidence. Even though a disturbed dopamine function has not yet been established beyond doubt in schizophrenia, recent basic research on dopaminergic mechanisms opens up possibilities for the development of more sophisticated pharmacologic tools, capable of discovering subtypes of dopamine receptors, which may turn out to be abnormal in schizophrenia. Such tools may also prove therapeutically useful. Schizophrenia is probably a heterogeneous group of disorders with mixed biopathology. To facilitate the search for nondopaminergic mechanisms of possible pathogenetic importance in subgroups of schizophrenia, a hypothetical model is presented that tries to explain the role of subcortical dopaminergic pathways for mental functions and their interaction with other systems. It is proposed that corticostriatothalamocortical negative feedback loops, also involving the mesencephalic reticular formation, are modulated by mesostriatal dopamine pathways to control a thalamic filter mechanism. The psychotomimetic actions of dopaminergic agents and phencyclidine may be due to interference with these feedback mechanisms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3075131     DOI: 10.1016/0893-133x(88)90012-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  158 in total

Review 1.  Drugs for a new millennium.

Authors:  S H Snyder
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-12-29       Impact factor: 6.237

2.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders.

Authors:  Pierre Sokoloff; Olivier Guillin; Jorge Diaz; Patrick Carroll; Nathalie Griffon
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 4.  Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Authors:  Andreas Heinz; Florian Schlagenhauf
Journal:  Schizophr Bull       Date:  2010-05-07       Impact factor: 9.306

5.  L-Dopa decarboxylase expression profile in human cancer cells.

Authors:  Ioanna Chalatsa; Eleftheria Nikolouzou; Emmanuel G Fragoulis; Dido Vassilacopoulou
Journal:  Mol Biol Rep       Date:  2010-06-11       Impact factor: 2.316

6.  Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study.

Authors:  Prachi Semwal; Suman Prasad; Panchami G Varma; A M Bhagwat; S N Deshpande; B K Thelma
Journal:  J Genet       Date:  2002-08       Impact factor: 1.166

7.  Association between schizophrenia and homozygosity at the dopamine D3 receptor gene.

Authors:  M A Crocq; R Mant; P Asherson; J Williams; Y Hode; A Mayerova; D Collier; L Lannfelt; P Sokoloff; J C Schwartz
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

Review 8.  Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes.

Authors:  William R Perlman; Cynthia Shannon Weickert; Mayada Akil; Joel E Kleinman
Journal:  J Psychiatry Neurosci       Date:  2004-07       Impact factor: 6.186

9.  Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression.

Authors:  G Gründer; H Wetzel; E Hammes; O Benkert
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Age-dependent loss of NMDA receptors in hippocampus, striatum, and frontal cortex of the rat: prevention by acetyl-L-carnitine.

Authors:  M Castorina; A M Ambrosini; L Pacific; M T Ramacci; L Angelucci
Journal:  Neurochem Res       Date:  1994-07       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.